3 completed, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Catalyst Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia MarzAA (marzeptacog alfa [activated]) - Hemophilia A, Hemophilia B | Phase 1 | Completed | Catalyst Biosciences | 11 | 2019-09-24 | 2021-09-13 |
| Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg, BeneFIX - Hemophilia B | Phase 1 | Completed | ISU Abxis Co., Ltd. | 11 | 2017-06-03 | 2020-11-10 |
| Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia PF-05280602 - Hemophilia A | Phase 1 | Completed | Catalyst Biosciences | 29 | 2011-12-01 | 2017-05-12 |
Hemophilia A (2) · Hemophilia B (2) · Factor VII Deficiency (1) · Thrombasthenia (1)
Factor IX (1) · marzeptacog alfa (activated) (1)
Italy (2) · Russia (2) · United States (2) · Belgium (1) · Bulgaria (1) · Hungary (1) · India (1) · New Zealand (1) · South Africa (1) · South Korea (1) · Turkey (Türkiye) (1) · Ukraine (1) · United Kingdom (1)
ChurWoo You, PhD (1) · Howard Levy, MD, PhD, MMM (1)